FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy By Ogkologos - July 1, 2026 120 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CADENZA study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Philanthropist Simon Collins: “I realised I could make a difference by... September 6, 2021 EMA Recommends Granting a Marketing Authorisation for Generic Sorafenib October 7, 2022 Breast Cancer Survivor’s Family Designs a Holiday Light Show in Her... December 15, 2020 Prognostic Significance of Lynch-like versus Sporadic MSI-H Endometrial Cancer Treated With... July 20, 2021 Load more HOT NEWS Evidence for the Utility of ctDNA Monitoring for Recurrence After CRC... TRACERx: Using blood tests to track lung cancer Strangers Buy Boy Stuffed Animals For His Birthday When His Mom... FDA Approves Pembrolizumab with Chemotherapy for HER2-negative Gastric or Gastro-Oesophageal Junction...
